美股异动 | 诺和诺德(NVO.US)涨逾4% 英批准Wegovy7.2毫克高剂量肥胖治疗方案

Core Viewpoint - Novo Nordisk's stock rose over 4% to $59.49 following the approval by the UK drug regulatory agency to increase the maximum weekly dosage of its popular weight loss drug Wegovy to 7.2 mg, providing broader treatment options for obesity patients [1] Group 1 - The UK Medicines and Healthcare products Regulatory Agency approved the new dosage regimen on January 6, breaking the previous limit of 2.4 mg [1] - Patients can now administer the higher dosage in three injections, enhancing the flexibility of treatment [1] - This approval is expected to positively impact the market for Wegovy, potentially increasing its adoption among healthcare providers and patients [1]